Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions frequently mention the breakthrough aspect of identifying biomarkers decades before symptoms, with phrases like 'missing a 34-year window' and 'potential to detect Alzheimer's early.' The tone often combines curiosity and optimism, emphasizing the promise of new diagnostic tools and early intervention strategies, which underscores the perceived significance and deep engagement with the research findings.
Most discussions acknowledge the significance of early biomarker changes and the potential for early detection to improve outcomes, as seen in comments about 'missing a 34-year intervention window' and 'early markers for Alzheimer’s.'
There is considerable curiosity about the implications, with posts highlighting the long preclinical phase and some suggesting innovations like 'nano-robots' or 'brain imaging' as key tools, showing high interest.
Several posts delve into detailed summaries of the study's findings, including specific changepoint years and the importance of different biomarkers, indicating deep engagement with the research.
Multiple comments emphasize the transformative potential of the research, mentioning how it could lead to early interventions and new diagnostic techniques, reflecting a perception of high impact.
Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alzheimer’s disease at least 10 years or more before the most common symptoms occur Read article: https://t.co/0WwJNtOyUd or blog post⬇https://t.co/TYugfs6sA5
Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alzheimer’s disease at least 10 years or more before the most common symptoms occur Read paper: https://t.co/0WwJNtOyUd or blog post ⬇ https://t.co/TYugfs6sA5
Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alzheimer’s disease at least 10 years or more before the most common symptoms occur Read article: https://t.co/0WwJNtOyUd or blog post⬇https://t.co/TYugfs6sA5
Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improve our track record in the race to find a therapy. #Alzheimers #StopAlz #EndAlz #EndAlzheimers @BrainCanada @TheADDF https://t.co/1hdw4AuTzO
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease: Laurent Younes, Marilyn Albert, Abhay Moghekar, Anja Soldan, Corinne Pettigrew, Michael I. Miller https://t.co/tZvrrWJ8fD
@Erichealthcoach Here's the study: Younes L, Albert M, Moghekar A, Soldan A, Pettigrew C, Miller MI. Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. Front Aging Neurosci. 2019 Apr 2;11:74. doi: 10.3389/fnagi.2019.00074. PMID: 31001108; PMCID:
Researchers identified biomarkers that can determine if an individual develops Alzheimer's years in advance, highlighting the long preclinical phase, with changes seen as early as 34 years prior to symptoms.
Researchers identified biomarkers that can detect Alzheimer's risk up to 34 years before symptoms, highlighting the extensive preclinical development phase of the disease through brain imaging, CSF analysis, and…
@NathanMoor61041 We're missing a 34-year intervention window. CSF tau changes that early before Alzheimer's symptoms (DOI: 10.3389/fnagi.2019.00074). Nano-robots detecting these changepoints could trigger targeted drug release decades before disease manifests. The tech isn't the barrier - it's
@Darusyaaa @BioProtocol
@Erichealthcoach Here's the study: Younes L, Albert M, Moghekar A, Soldan A, Pettigrew C, Miller MI. Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer's Disease. Front Aging Neurosci. 2019 Apr 2;11:74. doi: 10.3389/fnagi.2019.00074. PMID: 31001108; PMCID:
Frontiers | Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease | Frontiers in Aging Neuroscience https://t.co/wgmj3ed8zq
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/gUsjXVSg87
RT @FrontiersIn: Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alz…
Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alzheimer’s disease at least 10 years or more before the most common symptoms occur Read paper: https://t.co/0WwJNtOyUd or blog post ⬇ https://t.co/TYugfs6sA5
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/rox3wIKhXd
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/rox3wIKhXd
Identification des points de changement dans les #biomarqueur-s pendant la phase préclinique d'#Alzheimer https://t.co/K8aRyxf2uf anglais via Frontiers #science
Can #Alzheimer be predicted 10-30 years prior to symptoms onset? #ageing #biomarkers #HealthyLife #diagnostics #PrecisionMedicine #health #lifescience https://t.co/lGLpqnKihd
RT @Brain__News: "Brain imaging and spinal fluid analysis could help to guide the use of future preventive treatments for Alzheimer’s" htt…
"Brain imaging and spinal fluid analysis could help to guide the use of future preventive treatments for Alzheimer’s" https://t.co/FfnmL6aZld
RT @FrontiersIn: Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alz…
Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alzheimer’s disease at least 10 years or more before the most common symptoms occur Read article: https://t.co/0WwJNtOyUd or blog post⬇https://t.co/TYugfs6sA5
RT @FrontiersIn: Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alz…
Research in @FrontNeurosci suggests it may be possible to use #brainimaging & spinal fluid analysis to assess risk of #Alzheimer’s disease at least 10 years or more before the most common symptoms occur Read article: https://t.co/0WwJNtOyUd or blog post⬇https://t.co/TYugfs6sA5
New study identifies Alzheimer's years before symptoms occur - TomoNews https://t.co/Dw0yobTQ9l via @YouTube
https://t.co/jyu0ScEsPX
it may be possible to use brain imaging and spinal fluid analysis to assess the risk of Alzheimer’s disease at least 10 years. Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/0QqtOHjjkX
"Accumulating evidence indicates that the underlying neuropathological mechanisms associated with Alzheimer’s disease (AD) begin a decade or more before the emergence of mild cognitive impairment" https://t.co/XvydAujWSA
https://t.co/r9QeQZ1lhT
RT @ProMISinc: Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improv…
RT @ProMISinc: Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improv…
RT @ProMISinc: Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improv…
RT @ProMISinc: Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improv…
RT @ProMISinc: Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improv…
Amazing study shows biomarker change 34 years before onset of Alzheimer’s symptoms! New biomarkers could dramatically improve our track record in the race to find a therapy. #Alzheimers #StopAlz #EndAlz #EndAlzheimers @BrainCanada @TheADDF https://t.co/1hdw4AuTzO
https://t.co/WcZRqDgjGp
New study identifies Alzheimer's years before symptoms occur - TomoNews https://t.co/2EGdaF8hqh via @YouTube
RT @EDIMOSIP: https://t.co/wgGHFPQNop
https://t.co/wgGHFPQNop
RT @deustoNeuroLab: Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/YxFBNddzYy
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/YxFBNddzYy
Early markers for Alzheimer's disease https://t.co/N25gJ1aOFN
RT @FrontNeurosci: Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease: Laurent Younes, Marilyn Albe…
RT @FrontNeurosci: Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease: Laurent Younes, Marilyn Albe…
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease: Laurent Younes, Marilyn Albert, Abhay Moghekar, Anja Soldan, Corinne Pettigrew, Michael I. Miller https://t.co/tZvrrWJ8fD
RT @PharmacyOnline8: Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/ZubcfckcCg htt…
Identifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease https://t.co/ZubcfckcCg https://t.co/6bvlRMHh6Q
F
PN
FN
KS
A
W
RB
H
O
AS
DH
LV
FJ
EL
ひ
ČC
JM
AL
RS
DB
GD
JK
EP
P
DN
BD
SA
AL
OP